XML 81 R67.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
May 03, 2023
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Payments related to the settlement of the contingent consideration liability, Financing activities     $ 3,434 $ 32,798          
Payments related to the settlement of the contingent consideration liability, Operating activities     12,700 1,800          
Impairment of intangible assets $ 0   0            
Loss on disposition of business       1,254          
Interest income 221 $ 96 352 201          
Allowance for expected credit losses 296 192 296 192   $ 290 $ 281 $ 199 $ 199
Fibrovein Holdings Limited | Disposal Group, Not Discontinued Operations [Member]                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Loss on disposition of business   1,300              
Cash   1,000   1,000          
Inventory   1,200   1,200          
Reclassification of foreign currency translation gains   $ 1,000              
Bluegrass Vascular Technologies, Inc                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Impairment of equity method investment     270            
Ownership percentage         19.50%        
Equity method investment         $ 245        
STD Pharmaceutical Products Limited                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Impairment of intangible assets       $ 1,700          
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]       Asset Impairment Charges          
Selio                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Long-term notes receivable, net 2,400   2,400       2,400    
Allowance for expected credit losses 296   296       281    
Director | Cianna Medical                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Contingent payments related to acquisition     900 $ 1,600          
Other long-term obligations                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Contingent consideration liability, noncurrent 3,200   3,200       2,300    
Accrued expenses                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Contingent consideration liability, current $ 400   $ 400       $ 15,800